Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if BCYC is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
32 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 7 days ago
Red flags: 0
104 filers reported a long position in BCYC for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BAKER BROS. ADVISORS LP | $46.2M | 10.9M | Unchanged |
| FCPM III SERVICES B.V. | $14.7M | 3.5M | Unchanged |
| ARMISTICE CAPITAL, LLC | $14.4M | 3.4M | Unchanged |
| Long Focus Capital Management, LLC | $14M | 3.3M | Unchanged |
| ACADIAN ASSET MANAGEMENT LLC | $8.3M | 2M | Unchanged |
| RENAISSANCE TECHNOLOGIES LLC | $6.5M | 1.5M | +56.6% |
| GSK plc | $6.5M | 1.5M | Unchanged |
| PRICE T ROWE ASSOCIATES INC /MD/ | $3.8M | 902.2K | -12.3% |
| MARSHALL WACE, LLP | $3.4M | 797.9K | +111.5% |
| Qube Research & Technologies Ltd | $3.3M | 775.6K | +151.3% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.